Quick Answer
Bolt Biotherapeutics, Inc. reported Total Revenue of $7.70 million for fiscal year 2025.
Bolt Biotherapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $7.70M +0.1% |
$7.69M -2.4% |
$7.88M +37.5% |
$5.73M +354.7% |
$1.26M +445.5% |
$231.0K |
| Net Income | -$33.38M +47.1% |
-$63.12M +8.8% |
-$69.20M +21.5% |
-$88.10M +10.6% |
-$98.59M -62.3% |
-$60.73M |
| Diluted EPS | -$17.85 +46.0% |
-$33.06 -1706.6% |
-$1.83 +22.5% |
-$2.36 +20.5% |
-$2.97 | — |
| Total Assets | $56.75M -43.0% |
$99.63M -37.6% |
$159.78M -29.9% |
$227.81M -26.0% |
$307.72M +561.2% |
$46.54M |
| Cash and Equivalents | $11.70M +62.4% |
$7.21M -33.3% |
$10.81M +16.9% |
$9.24M -66.2% |
$27.38M +394.1% |
$5.54M |
| Stockholders Equity | $26.50M -53.7% |
$57.20M -49.3% |
$112.74M -34.3% |
$171.51M -31.4% |
$250.12M +338.3% |
-$104.95M -128.9% |
| R&D Expense | $28.53M -50.4% |
$57.47M -6.6% |
$61.54M -15.8% |
$73.12M -3.3% |
$75.66M +87.5% |
$40.36M |
| Operating Income | -$36.11M +50.6% |
-$73.05M +4.1% |
-$76.20M +15.6% |
-$90.32M +2.7% |
-$92.79M -88.7% |
-$49.18M |
| Shares Outstanding | 1.92M +0.2% |
1.92M -95.0% |
38.11M +0.8% |
37.80M +1.1% |
37.40M +1655.7% |
2.13M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.17M | +90.1% | +20.2% |
| Net Income | September 30, 2025 | -$7.14M | +52.9% | +16.6% |
| Diluted EPS | September 30, 2025 | -$3.72 | +53.1% | +16.6% |
| Total Assets | September 30, 2025 | $65.05M | -40.5% | -13.8% |
| Cash and Equivalents | September 30, 2025 | $17.75M | +89.5% | +84.9% |
| Stockholders Equity | September 30, 2025 | $32.10M | -55.4% | -17.4% |
| R&D Expense | September 30, 2025 | $6.54M | -52.6% | -12.8% |
| Operating Income | September 30, 2025 | -$7.70M | +53.2% | +16.4% |
| Shares Outstanding | September 30, 2025 | 1.92M | -95.0% | +0.0% |
- Bolt Biotherapeutics, Inc. reported Total Revenue of $7.70 million for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +0.1% in Total Revenue compared to the prior fiscal year.
- Bolt Biotherapeutics, Inc. reported Net Income of -$33.38 million for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +47.1% in Net Income compared to the prior fiscal year.
- Bolt Biotherapeutics, Inc. reported Diluted EPS of $17.85 per share (loss) for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +46.0% in Diluted EPS compared to the prior fiscal year.
- Bolt Biotherapeutics, Inc. reported Total Assets of $56.75 million for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed a decrease of -43.0% in Total Assets compared to the prior fiscal year.
- Bolt Biotherapeutics, Inc. reported Cash and Equivalents of $11.70 million for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +62.4% in Cash and Equivalents compared to the prior fiscal year.
- Bolt Biotherapeutics, Inc. reported Stockholders Equity of $26.50 million for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed a decrease of -53.7% in Stockholders Equity compared to the prior fiscal year.
- Bolt Biotherapeutics, Inc. reported R&D Expense of $28.53 million for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed a decrease of -50.4% in R&D Expense compared to the prior fiscal year.
- Bolt Biotherapeutics, Inc. reported Operating Income of -$36.11 million for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +50.6% in Operating Income compared to the prior fiscal year.
- Bolt Biotherapeutics, Inc. reported Shares Outstanding of 1.92 million shares for fiscal year 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +0.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: